Peruvoside - Misplaced Pages

Chemical compound Pharmaceutical compound

Peruvoside
Clinical data

Other names	(3S,5R,10R,13R,14S,17R)- 3-oxy- 14-hydroxy- 13-methyl- 17-(5-oxo-2H-furan-3-yl)- 1,2,3,4,5,6,7,8,9,11,12,15,16,17- tetradecahydrocyclopentaphenanthrene- 10-carbaldehyde
ATC code	C01AX02 (WHO)
Identifiers
IUPAC name (3β,5β,8ξ,9ξ)- 3-- 14-hydroxy- 19-oxocard- 20(22)enolide
CAS Number	1182-87-2
PubChem CID	14449
ChemSpider	16498835
UNII	CT36KGC6A6
ChEMBL	ChEMBL1075790
CompTox Dashboard (EPA)	DTXSID70881388
ECHA InfoCard	100.013.327
Chemical and physical data
Formula	C₃₀H₄₄O₉
Molar mass	548.673 g·mol
3D model (JSmol)	Interactive image
SMILES O=C\1OC/C(=C/1)6CC5(O)6(C)CC35CC4C(O2O(C)(O)(OC)2O)CC34C=O
InChI InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,15-16,18-22,24-27,33-35H,4-11,13-14H2,1-3H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28+,29+,30-/m0/s1 Key:PMTSPAGBAFCORP-HBUONDEYSA-N
(what is this?) (verify)

This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (February 2021) (Learn how and when to remove this message)

Peruvoside (or cannogenin thevetoside) is a cardiac glycoside for heart failure.

It is derived from Cascabela thevetia (Thevetia neriifolia).

References

Arora RB, Rangaswami S (1972). Peruvoside and Other Cardiotonic Glycoside of Thevetia neriifolia Juss: Chemical, Pharmacological, and Clinical Studies. New Delhi, India: Thomson. LCCN 78900408.
^ Bhatia ML, Manchanda SC, Roy SB (September 1970). "Haemodynamic studies with peruvoside in human congestive heart failure". British Medical Journal. 3 (5725): 740–3. doi:10.1136/bmj.3.5725.740. PMC 1701679. PMID 4919553.

Cardiac glycosides (C01A)

Bufadienolides

Bufo	Arenobufagin Bufotalin Cinobufagin Marinobufagin
Scilla	Proscillaridin Scilliroside
Kalanchoe	Daigremontianin

Cardenolides

Digitalis	Acetyldigitoxin Acetyldigoxin Digitoxin Digoxin Lanatoside C Deslanoside Metildigoxin Gitoformate
Strophanthus	Ouabain (g-Strophanthin) k-Strophanthin Cymarin
Thevetia	Peruvoside

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: